Skip to main content

Table 1 Demographic and clinicopathological variables of the 330 investigated stage III colon cancer patients

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Variables All patients [cases (%)]
Age [median (range), years] 55 (19–85)
Gender
 Male 189 (57.3)
 Female 141 (42.7)
BMI [median (range), kg/m2] 22.3 (14.3–34.2)
Tumor size [median (range), cm] 4 (0.8–15)
Tumor location
 Cecum 15 (4.5)
 Ascending colon 55 (16.7)
 Hepatic flexure 30 (9.1)
 Transverse colon 31 (9.4)
 Splenic flexure 6 (1.8)
 Descending colon 31 (9.4)
 Sigmoid colon 162 (49.1)
Tumor differentiation
 Well/moderately differentiated 238 (72.1)
 Poor/undifferentiated 92 (27.9)
T stage
 T1–2 16 (4.8)
 T3 156 (47.3)
 T4 158 (47.9)
No. of resected lymph nodes [median (range)] 15 (2–63)
N stage
 N1 233 (70.6)
 N2 97 (29.4)
Preoperative serum CEA (ng/mL)
 ≤ 5 199 (60.3)
 > 5 131 (39.7)
Preoperative serum CA19-9 (U/mL)
 ≤ 24 228 (69.1)
 > 24 102 (30.9)
Risk stratification
 Low risk 131 (39.7)
 High risk 199 (60.3)
  1. BMI body mass index, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9